ViaCord Speaker Spotlight
Therapeutic Potential of Heterogeneous Cells Isolated Directly from Cord Tissue
Morey Kraus, Chief Scientific Officer
The International Society for Cellular Therapy (ISCT) is a global society of clinicians, regulators, technologists, and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients’ lives. Each year ISCT gathers for an annual meeting that brings great minds together to share work and progress toward advancing therapies for the benefit of patients worldwide.
This year, over 1200 international delegates are expected to be in attendance at the 21st annual ISCT meeting. Attendees can expect to hear from clinicians, laboratory professionals, industry leaders from cellular therapy companies, and ViaCord’s very own Chief Scientific Officer, Morey Kraus! Not only is Morey part of the speaker program, he – along with a team from ViaCord – will also have an abstract poster on display.
ViaCord Speaker Spotlight
Novel Applications for Cord Blood: Exploring Regenerative Properties
Kate Girard, RN MSN, Senior Principal Clinical Affairs Specialist
We are excited to share that ViaCord’s own Kate Girard is not only attending, but is also speaking at the Cord Blood World Europe Conference occurring in London this Wednesday and Thursday. We are excited that Kate is able to attend this meeting because it offers her an opportunity to educate other industry professionals as well as bring back valuable knowledge to the ViaCord research team.This conference is all about advancing cord blood medicine and learning about the latest developments in therapeutic applications for cord blood. Over the course of two days, cord blood bank representatives, clinicians, and researchers will all gather together to discuss how to build deposits, reduce the costs of banking, and increase utilization. Read More
Tracking Stem Cells After Infusion
via Parents Guide to Cord Blood Banking
For the last decade, Dr. Assaf A. Gilad, PhD, Associate Professor at Johns Hopkins University, and his lab have been developing a unique imaging technology that not only tracks the location of transplanted stem cells post infusion, it also monitors cell viability and function – all in a non-invasive way.
Researchers continue to probe for new possibilities using cord blood stem cells (a top reason why families bank). With their instant availability and proven usefulness in helping treat a number of diseases today, cord blood stem cells have become a valuable medical resource for doctors. Recently, the Mayo Clinic announced a Phase 1 Clinical Trial that will look at the safety and feasibility of using a newborn’s own umbilical cord blood stem cells as a potential additional treatment for the management of hypoplastic left heart syndrome (HLHS). This marks the first stem cell clinical trial for pediatric congenital heart disease in the United States.
HLHS – A Challenging Road to Travel
Hypoplastic left heart syndrome has long been considered one of cardiology’s most challenging congenital heart defects. According to the Centers for Disease and Prevention Center approximately 1000 babies (1 out of every 4,350) are born each year in the US with the condition.1 In HLHS newborns are born with severely underdeveloped structures on the left side of the heart. This results in the Read More
Approximately 5.4 million people in the United States are living with Alzheimer’s disease – one in eight older Americans suffers from this condition.1 It’s an irreversible, progressive brain disease that negatively impacts memory and cognitive skills. With no known cure today, the scientific community continues to research potential new treatment options, including the potential use of umbilical cord blood and cord tissue stem cells.
Umbilical cord tissue offers an abundant source of Mesenchymal Stem Cells (MSCs). These stem cells are expected to play a critical role in the treatment of disease and are being studied in great detail for their regenerative properties in cartilage, muscle, and nerve cells. In Alzheimer’s the dysfunction of a certain type of neuron (nerve cell), called the cholinergic neuron, is one cause of cognitive disorder in patients.
Osteoarthritis occurs when the protective cartilage on the ends of bones wears down over time. It’s the most common form of arthritis, affecting millions of people around the world. Following a joint injury the chance of developing a type of osteoarthrisis, called post-traumatic arthritis (PTA) increases greatly.1 Although no cure exists today, a recent study funded by the Arthritis Foundation and National Institute of Health demonstrated a stem cell therapy that could potentially be used after a joint injury to prevent the onset of PTA.
For the therapy researchers at Duke University Health System used a specific group of stem cells, called mesenchemyal stem cells (MSCs), because of their beneficial properties in other areas of the body. The MSCs were extracted from bone marrow of mice, expanded to achieve a purified source of cells, and then delivered to the joints of mice with fractures that typically would lead to them developing arthritis. The result?